EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer

Yong Wu, Siyu Chen, Yang Shao, Ying Su, Qin Li, Jiangchun Wu, Jun Zhu, Hao Wen, Yan Huang, Zhong Zheng, Xiaojun Chen, Xingzhu Ju und 3 weitere

Advanced Science · 2023-11 · 10 (31)

DOI: 10.1002/advs.202304638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 13.09.2023. Verfasst von Yong Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-laborat…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ovarian Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One major characteristic of tumor cells is the aberrant activation of epigenetic regulatory elements, which remodel the tumor transcriptome and ultimately promote cancer progression and drug resistance. However, the oncogenic functions and mechanisms of ovarian cancer (OC) remain elusive. Here, super‐enhancer (SE) regulatory elements that are aberrantly activated in OC are identified and it is found that SEs drive the relative specific expression of the transcription factor KLF5 in OC patients and poly(ADP‐ribose) polymerase inhibitor (PARPi)‐resistant patients. KLF5 expression is associated with poor outcomes in OC patients and can drive tumor progression in vitro and in vivo. Mechanistically, KLF5 forms a transcriptional complex with EHF and ELF3 and binds to the promoter region of RAD51 to enhance its transcription, strengthening the homologous recombination repair (HRR) pathway. Notably, the combination of suberoylanilide hydroxamic acid (SAHA) and olaparib significantly inhibits tumor growth and metastasis of PARPi‐resistant OC cells with high KLF5 . In conclusion, it is discovered that SEs‐driven KLF5 is a key regulatory factor in OC progression and PARPi resistance; and potential therapeutic strategies for OC patients with PARPi resistance and high KLF5 are identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsOvarian NeoplasmsHumansFemalePoly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmVorinostatKruppel-Like Transcription Factors

Stichwörter der Autor:innen

KLF5PARPi resistanceRAD51homologous recombination repairovarian cancersuper-enhancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsVorinostatKLF5 protein, humanKruppel-Like Transcription Factors

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sc…
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

ORCID-Profile: Zhixiang Hu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Sailing Program

Zitieren

APA

Wu, Y., Chen, S., Shao, Y., Su, Y., Li, Q., Wu, J., Zhu, J., Wen, H., Huang, Y., Zheng, Z., Chen, X., Ju, X., Huang, S., Wu, X., & Hu, Z. (2023). KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer. Advanced Science, 10(31). https://doi.org/10.1002/advs.202304638

Vancouver

Wu Y, Chen S, Shao Y, Su Y, Li Q, Wu J, et al. KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer. Advanced Science. 2023;10(31). doi:10.1002/advs.202304638

BibTeX
@article{Wu2023,
  author = {Wu, Yong and Chen, Siyu and Shao, Yang and Su, Ying and Li, Qin and Wu, Jiangchun and Zhu, Jun and Wen, Hao and Huang, Yan and Zheng, Zhong and Chen, Xiaojun and Ju, Xingzhu and Huang, Shenglin and Wu, Xiaohua and Hu, Zhixiang},
  title = {KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {31},
  doi = {10.1002/advs.202304638}
}
Kostenlos starten →